- Trade options, futures, options on futures, stocks, ETFs
- $0 commission to close options
- Pro-grade platform and risk analysis tools
Finder makes money from featured partners, but editorial opinions are our own.
Advertiser disclosure
Compass Therapeutics is a biotechnology business based in the US. Compass Therapeutics shares (CMPX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.38 – a decrease of 5.48% over the previous week. Compass Therapeutics employs 32 staff and has a trailing 12-month revenue of around $850,000.
Our top picks for where to buy Compass Therapeutics stock
- Trade $0 commission stocks & ETFs with as little as $1
- Earn up to $300 with qualifying deposits
- Discover new opportunities with Opto's AI-driven thematic investing system
- Theme and ETF screener
- Trade stocks, options, ETFs, mutual funds, alternative asset funds
- $0 commission on stocks, ETFs and options with no options contract fees
- Get up to $1,000 in stock when you fund a new account within 30 days
- Complimentary access to a financial planner
Probability of member receiving $1,000 is 0.028%
How to buy Compass Therapeutics stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – CMPX. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Compass Therapeutics stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.1 - 4 of 4
What is the Finder Score?
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Compass Therapeutics stock price (NASDAQ: CMPX)
Use our graph to track the performance of CMPX stocks over time.Compass Therapeutics shares at a glance
Information last updated 2024-12-19.
| Latest market close | $1.38 |
|---|---|
| 52-week range | $0.77 - $2.34 |
| 50-day moving average | $1.67 |
| 200-day moving average | $1.51 |
| Wall St. target price | $8.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.35 |
Is it a good time to buy Compass Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Compass Therapeutics price performance over time
Historical closes compared with the close of $1.38 from 2024-12-20
| 1 week (2024-12-13) | -5.48% |
|---|---|
| 1 month (2024-11-22) | -7.38% |
| 3 months (2024-09-20) | -16.87% |
| 6 months (2024-06-21) | 25.45% |
| 1 year (2023-12-21) | -15.34% |
|---|---|
| 2 years (2022-12-21) | -73.15% |
| 3 years (2021-12-21) | 3.03 |
| 5 years (2019-12-18) | N/A |
Compass Therapeutics financials
| Revenue TTM | $850,000 |
|---|---|
| Gross profit TTM | $0 |
| Return on assets TTM | -21.71% |
| Return on equity TTM | -32% |
| Profit margin | 0% |
| Book value | $1.01 |
| Market Capitalization | $195.4 million |
TTM: trailing 12 months
Compass Therapeutics share dividends
We're not expecting Compass Therapeutics to pay a dividend over the next 12 months.
You may also wish to consider:
Compass Therapeutics share price volatility
Over the last 12 months, Compass Therapeutics's shares have ranged in value from as little as $0.765 up to $2.34. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Compass Therapeutics's is 0.746. This would suggest that Compass Therapeutics's shares are less volatile than average (for this exchange).
To put Compass Therapeutics's beta into context you can compare it against those of similar companies.
- Surface Oncology (SURF.US): 1.7527
- Jounce Therapeutics (JNCE.US): 0.7512
- Relay Therapeutics Inc (RLAY.US): 1.675
Compass Therapeutics overview
Compass Therapeutics, Inc. , a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts. .
Frequently asked questions
nullWhat percentage of Compass Therapeutics is owned by insiders or institutions?
Currently 12.55% of Compass Therapeutics shares are held by insiders and 71.756% by institutions. How many people work for Compass Therapeutics?
Latest data suggests 32 work at Compass Therapeutics. When does the fiscal year end for Compass Therapeutics?
Compass Therapeutics's fiscal year ends in December. Where is Compass Therapeutics based?
Compass Therapeutics's address is: 80 Guest Street, Boston, MA, United States, 02135 What is Compass Therapeutics's ISIN number?
Compass Therapeutics's international securities identification number is: US20454B1044
More resources on Finder
More guides on Finder
-
Best Stocks for Beginners With Little Money to Invest
These are the stocks to buy when you don’t have much to spend.
-
Sweep Accounts
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
-
Today’s Best Brokerage Account Bonuses [Signup and Transfer Promos]
Explore the best bonuses for opening a new brokerage account.
-
Trading for Beginners: 9 Best Trading Platforms to Get Started
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
-
5 Top Graphene Stocks to Invest in Today
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
-
10 Best Brokerage Accounts for Trading and Investing in 2024
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
-
Ratings methodology for online brokers
Our star ratings for online brokerages are based on how they stack up in nine key categories.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
How to Invest $10K
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
-
5 best ETFs for 2024
Check out the best-performing ETFs so far in 2024.
Ask a question